293 completed, 111 recruiting, 69 not yet recruiting, 56 active not recruiting. 159 Phase 3, 121 Phase 2, 108 Phase 1, 92 Phase 4, 44 Not applicable.
Follow semaglutide: new trials by email Literature Review of semaglutide trials Research Report on semaglutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) Semaglutide (SEMA), Exercise module, Anti-inflammatory diet module - Severe Mental Illness, Depression / Major Depressive Disorder | Not applicable | Not yet recruiting | Ludwig-Maximilians - University of Munich | 140 | 2028-10-01 | 2026-05-14 |
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2 / Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 226 | 2027-09-01 | 2026-09-28 |
| GLP-1 RA for Stage 1 Type 1 Diabetes Semaglutide, Placebo - Stage 1 Diabetes Mellitus, Type 1 | Phase 2 | Not yet recruiting | Children's Hospital Medical Center, Cincinnati | 15 | 2027-09-01 | 2026-02-24 |
| Semaglutide for Low Back Pain Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector) - Lower Back Pain, Obesity (BMI>30) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 250 | 2027-02-01 | 2026-07-28 |
| Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea Semaglutide - Diabetes Mellitus, Type 2 | Not yet recruiting | Novo Nordisk A/S | 600 | 2027-01-31 | 2026-09-18 | |
| Semaglutide for the Treatment of Cannabis Use Disorder semaglutide - Cannabis Use Disorder, Cue-reactivity | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 40 | 2027-01-10 | 2026-10-19 |
| Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access Semaglutide, Virtual Weight Management Coaching - Obesity, Chronic Kidney Disease | Phase 4 | Not yet recruiting | Kristin Clemens | 880 | 2027-01-01 | 2026-10-05 |
| SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®), Placebo (saline injection) - Type 1 Diabetes Mellitus | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 240 | 2027-01-01 | 2026-05-29 |
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program - Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 48 | 2027-01-01 | 2026-10-01 |
| SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | Not yet recruiting | Hospital Universitari de Bellvitge | 80 | 2027-01-01 | 2026-06-10 |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 600 | 2026-12-01 | 2026-08-18 |
| GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward Semaglutide - Obesity, Childhood | Phase 4 | Not yet recruiting | University of Minnesota | 1020 | 2026-11-15 | 2026-10-20 |
| Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Maridebart cafraglutide, Semaglutide - Diabetes Mellitus, Type 2 | Phase 3 | Not yet recruiting | Amgen | 1300 | 2026-11-02 | 2026-10-08 |
| SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child | Phase 3 | Not yet recruiting | University Hospital, Angers | 50 | 2026-11-01 | 2026-09-29 |
| GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease Semaglutide, Weight reduction recommendations (nutritional and exercise) - Adiposity, Fatty Liver | Not applicable | Not yet recruiting | Insel Gruppe AG, University Hospital Bern | 64 | 2026-11-01 | 2026-08-19 |
| Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy Semaglutide - Ischemic Stroke | Phase 2 | Not yet recruiting | Population Health Research Institute | 100 | 2026-10-31 | 2026-09-24 |
| Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants JMT206 injection, Semaglutide injection, Placebo injection - Valid MeSH Conditiongs | Phase 1 | Not yet recruiting | Shanghai JMT-Bio Inc. | 90 | 2026-10-20 | 2026-09-25 |
| Long-Term Effects of Semaglutide on Body Composition and Performance in Running Semaglutide (SEMA), Placebo - Caloric Restriction, Body Composition | Not applicable | Not yet recruiting | Morten Hostrup, PhD | 41 | 2026-10-14 | 2026-10-15 |
| Short Term Effects of Semaglutide on Body Composition and Performance Semaglutide (SEMA), Placebo - Caloric Restriction, Body Composition | Not applicable | Not yet recruiting | Morten Hostrup, PhD | 41 | 2026-10-14 | 2026-10-15 |
| Semaglutide Health Outcomes and Patient Adherence in Australia Semaglutide - Overweight, Obesity | Not yet recruiting | Novo Nordisk A/S | 10000 | 2026-10-13 | 2026-10-19 |
Showing 20 of 590. Sign in to see all of them.
Diabetes Mellitus, Type 2 (244) · Obesity (208) · Overweight (84) · Diabetes Mellitus (81) · Weight Loss (25) · Non-alcoholic Fatty Liver Disease (21) · Renal Insufficiency, Chronic (18) · Diabetes Mellitus, Type 1 (14) · Cardiovascular Diseases (11) · Alcoholism (10) · Metabolic Syndrome (10) · Insulin Resistance (9) · Prediabetic State (9) · Inflammation (8) · Body Weight (7)
Novo Nordisk A/S (233) · Brigham and Women's Hospital (13) · Eli Lilly and Company (7) · University of Colorado, Denver (7) · Mayo Clinic (6) · University Medical Centre Ljubljana (5) · Vanderbilt University Medical Center (5) · Yale University (5) · Boehringer Ingelheim (4) · Chinese University of Hong Kong (4) · AstraZeneca (3) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (3) · Merck Sharp & Dohme LLC (3) · Pfizer (3) · RenJi Hospital (3)
United States (227) · Germany (101) · Canada (87) · China (73) · United Kingdom (68) · Denmark (64) · Spain (59) · Poland (58) · Japan (54) · Hungary (41) · Italy (41) · Mexico (39) · India (37) · Australia (35) · Bulgaria (35)
Shirley Wang, PhD, ScM (8) · Aaron Kelly, PhD (2)
PMID 31903692, PMID 32998732, PMID 32267058, PMID 39963952, PMID 30615985, PMID 31769496, PMID 39535683, PMID 35373893, PMID 29766634, PMID 29862621, PMID 29907893, PMID 30122305, PMID 31215727, PMID 33660198, PMID 33969456, PMID 29687620, PMID 29748996, PMID 32193837, PMID 32827435, PMID 35383100, PMID 36056351, PMID 37178435, PMID 38698650, PMID 39222642, PMID 39226070, PMID 27633186, PMID 33567185, PMID 34472698, PMID 35724304, PMID 36801984, PMID 39480988, PMID 40980163, PMID 28110911, PMID 28349387, PMID 28526920, PMID 29246950, PMID 29764222, PMID 33185364, PMID 33606902, PMID 33667417, PMID 33782832, PMID 34080123, PMID 35064550, PMID 35434913, PMID 35439567, PMID 35484580, PMID 35582947, PMID 36200477, PMID 36738088, PMID 37605636
2019 (20), 2023 (16), 2017 (13), 2018 (13), 2015 (12), 2025 (12), 2016 (5), 2014 (4), 2008 (2), 2009 (1), K12AR084234 (1), K23DK131345 (1), K23HL183845 (1), P01AA029545 (1), P30AG044271 (1)